122 related articles for article (PubMed ID: 1795229)
1. [Once-a-month injectable microcapsules of leuprorelin acetate].
Toguchi H; Ogawa Y; Okada H; Yamamoto M
Yakugaku Zasshi; 1991 Aug; 111(8):397-409. PubMed ID: 1795229
[TBL] [Abstract][Full Text] [Related]
2. [Design and development of controlled release of drugs from injectable microcapsules].
Takada S; Ogawa Y
Nihon Rinsho; 1998 Mar; 56(3):675-9. PubMed ID: 9549355
[TBL] [Abstract][Full Text] [Related]
3. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats.
Okada H; Heya T; Ogawa Y; Shimamoto T
J Pharmacol Exp Ther; 1988 Feb; 244(2):744-50. PubMed ID: 3126294
[TBL] [Abstract][Full Text] [Related]
4. Formulation study of leuprorelin acetate to improve clinical performance.
Toguchi H
Clin Ther; 1992; 14 Suppl A():121-30. PubMed ID: 1606592
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical manipulation of leuprorelin acetate to improve clinical performance.
Toguchi H
J Int Med Res; 1990; 18 Suppl 1():35-41. PubMed ID: 2138986
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of depot leuprorelin.
Periti P; Mazzei T; Mini E
Clin Pharmacokinet; 2002; 41(7):485-504. PubMed ID: 12083977
[TBL] [Abstract][Full Text] [Related]
7. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.
Plosker GL; Brogden RN
Drugs; 1994 Dec; 48(6):930-67. PubMed ID: 7533699
[TBL] [Abstract][Full Text] [Related]
8. Effects of TAP-144-SR, a sustained-release formulation of a potent GnRH agonist, on experimental endometriosis in the rat.
Sudo K; Shiota K; Masaki T; Fujita T
Endocrinol Jpn; 1991 Feb; 38(1):39-45. PubMed ID: 1915112
[TBL] [Abstract][Full Text] [Related]
9. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate.
Okada H
Adv Drug Deliv Rev; 1997 Oct; 28(1):43-70. PubMed ID: 10837564
[TBL] [Abstract][Full Text] [Related]
10. Controlled-release of leuprolide acetate from polylactic acid or copoly(lactic/glycolic) acid microcapsules: influence of molecular weight and copolymer ratio of polymer.
Ogawa Y; Yamamoto M; Takada S; Okada H; Shimamoto T
Chem Pharm Bull (Tokyo); 1988 Apr; 36(4):1502-7. PubMed ID: 3138032
[No Abstract] [Full Text] [Related]
11. Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers.
Okada H; Doken Y; Ogawa Y; Toguchi H
Pharm Res; 1994 Aug; 11(8):1143-7. PubMed ID: 7971715
[TBL] [Abstract][Full Text] [Related]
12. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
[TBL] [Abstract][Full Text] [Related]
13. In vivo characteristics of low molecular weight copoly (D,L-lactic acid) formulations with controlled release of LH-RH agonist.
Asano M; Fukuzaki H; Yoshida M; Kumakura M; Mashimo T; Yuasa H; Imai K; Yamanaka H
Biomaterials; 1989 Oct; 10(8):569-73. PubMed ID: 2513891
[TBL] [Abstract][Full Text] [Related]
14. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid.
Ogawa Y; Yamamoto M; Okada H; Yashiki T; Shimamoto T
Chem Pharm Bull (Tokyo); 1988 Mar; 36(3):1095-103. PubMed ID: 3136939
[No Abstract] [Full Text] [Related]
15. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
[TBL] [Abstract][Full Text] [Related]
16. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
[TBL] [Abstract][Full Text] [Related]
17. Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations.
Goto R; Uda A; Hiroi S; Iwasaki K; Takashima K; Oya M
J Med Econ; 2017 Nov; 20(11):1155-1162. PubMed ID: 28758810
[TBL] [Abstract][Full Text] [Related]
18. An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer.
Sartor O; Dineen MK; Perez-Marreno R; Chu FM; Carron GJ; Tyler RC
Urology; 2003 Aug; 62(2):319-23. PubMed ID: 12893343
[TBL] [Abstract][Full Text] [Related]
19. Persistent suppression of the pituitary-gonadal system in female rats by three-month depot injectable microspheres of leuprorelin acetate.
Okada H; Doken Y; Ogawa Y
J Pharm Sci; 1996 Oct; 85(10):1044-8. PubMed ID: 8897268
[TBL] [Abstract][Full Text] [Related]
20. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer.
Sethi R; Sanfilippo N
Clin Interv Aging; 2009; 4():259-67. PubMed ID: 19554097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
